| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imaging, Diagnosis, Prognosis |
Authors' Affiliations: 1 Rush University Medical Center, Chicago, Illinois and 2 Genomic Health, Inc., Redwood City, California
Requests for reprints: Melody A. Cobleigh, Rush University Medical Center, Professional Building, 1725 West Harrison, Suite 821, Chicago, IL 60612. Phone: 312-942-2242; Fax: 312-563-3123; E-mail: melody_cobleigh{at}rush.edu.
Purpose: This study, along with two others, was done to develop the 21-gene Recurrence Score assay (Oncotype DX) that was validated in a subsequent independent study and is used to aid decision making about chemotherapy in estrogen receptor (ER)–positive, node-negative breast cancer patients.
Experimental Design: Patients with 
10 nodes diagnosed from 1979 to 1999 were identified. RNA was extracted from paraffin blocks, and expression of 203 candidate genes was quantified using reverse transcription-PCR (RT-PCR).
Results: Seventy-eight patients were studied. As of August 2002, 77% of patients had distant recurrence or breast cancer death. Univariate Cox analysis of clinical and immunohistochemistry variables indicated that HER2/immunohistochemistry, number of involved nodes, progesterone receptor (PR)/immunohistochemistry (% cells), and ER/immunohistochemistry (% cells) were significantly associated with distant recurrence-free survival (DRFS). Univariate Cox analysis identified 22 genes associated with DRFS. Higher expression correlated with shorter DRFS for the HER2 adaptor GRB7 and the macrophage marker CD68. Higher expression correlated with longer DRFS for tumor protein p53-binding protein 2 (TP53BP2) and the ER axis genes PR and Bcl2. Multivariate methods, including stepwise variable selection and bootstrap resampling of the Cox proportional hazards regression model, identified several genes, including TP53BP2 and Bcl2, as significant predictors of DRFS.
Conclusion: Tumor gene expression profiles of archival tissues, some more than 20 years old, provide significant information about risk of distant recurrence even among patients with 10 or more nodes.
This article has been cited by other articles:
|
|
 |
|
  A. Russom, P. Sethu, D. Irimia, M. N. Mindrinos, S. E. Calvano, I. Garcia, C. Finnerty, C. Tannahill, A. Abouhamze, J. Wilhelmy, et al. Microfluidic Leukocyte Isolation for Gene Expression Analysis in Critically Ill Hospitalized Patients Clin. Chem., May 1, 2008; 54(5): 891 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ross, C. Hatzis, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer Oncologist, May 1, 2008; 13(5): 477 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. N. Harris, D. F. Hayes, and R. C. Bast In Reply J. Clin. Oncol., April 20, 2008; 26(12): 2060 - 2061. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Marchionni, R. F. Wilson, A. C. Wolff, S. Marinopoulos, G. Parmigiani, E. B. Bass, and S. N. Goodman Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer Ann Intern Med, March 4, 2008; 148(5): 358 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Bai and S.-W. Luoh GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation Carcinogenesis, March 1, 2008; 29(3): 473 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cronin, C. Sangli, M.-L. Liu, M. Pho, D. Dutta, A. Nguyen, J. Jeong, J. Wu, K. C. Langone, and D. Watson Analytical Validation of the Oncotype DX Genomic Diagnostic Test for Recurrence Prognosis and Therapeutic Response Prediction in Node-Negative, Estrogen Receptor-Positive Breast Cancer Clin. Chem., June 1, 2007; 53(6): 1084 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Paik Development and Clinical Utility of a 21-Gene Recurrence Score Prognostic Assay in Patients with Early Breast Cancer Treated with Tamoxifen Oncologist, June 1, 2007; 12(6): 631 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Stafford and M. Brun Three methods for optimization of cross-laboratory and cross-platform microarray expression data Nucleic Acids Res., May 11, 2007; 35(10): e72 - e72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Hicks, B. J. Yoder, S. Short, S. Tarr, N. Prescott, J. P. Crowe, A. E. Dawson, G. T. Budd, S. Sizemore, M. Cicek, et al. Loss of Breast Cancer Metastasis Suppressor 1 Protein Expression Predicts Reduced Disease-Free Survival in Subsets of Breast Cancer Patients. Clin. Cancer Res., November 15, 2006; 12(22): 6702 - 6708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Azad, N. Rasool, C. M. Annunziata, L. Minasian, G. Whiteley, and E. C. Kohn Proteomics in Clinical Trials and Practice: Present Uses and Future Promise Mol. Cell. Proteomics, October 1, 2006; 5(10): 1819 - 1829. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
